Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Friedecký

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Open Biology|January 8, 2016
Dr Jekyll and Mr Hyde: a strange case of 5-ethynyl-2'-deoxyuridine and 5-ethynyl-2'-deoxycytidineAnna Ligasová, Radek Liboska, David Friedecký, et al.
Analytical and Bioanalytical Chemistry|May 27, 2026
Derivatisation-free FIA-MS/MS assay for rapid simultaneous screening of atypical myopathy biomarkers and acylcarnitine profiles from dried blood spotsMartina Kadláčková, Dana Dobešová, Eliška Ivanovová, et al.
Talanta|April 18, 2015
Oxidized phosphatidylcholines suggest oxidative stress in patients with medium-chain acyl-CoA dehydrogenase deficiencyLukáš Najdekr, Alžběta Gardlo, Lucie Mádrová, et al.
International Journal of Molecular Sciences|August 7, 2021
SLIDE-Novel Approach to Apocrine Sweat Sampling for Lipid Profiling in Healthy IndividualsAleš Kvasnička, David Friedecký, Alena Tichá, et al.
Alzheimer'S Research & Therapy|September 23, 2017
Metabolic status of CSF distinguishes rats with tauopathy from controlsRadana Karlíková, Kateřina Mičová, Lukáš Najdekr, et al.
Annals of Hematology|January 11, 2012
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical settingEdgar Faber, David Friedecký, Kateřina Mičová, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive PatientsJana Úlehlová, Barbora Piskláková, Eliška Ivanovová, et al.
Progress in Neurobiology|February 6, 2026
ABCA7 deficiency exacerbates glutamate excitotoxicity in Alzheimer's disease mice - a new pharmacological target for Glu-related neurotoxicityAnna Maria Górska, Irene Santos-García, Aleš Kvasnička, et al.
European Journal of Medical Research|January 6, 2024
Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosisKateřina Klíčová, Jan Mareš, Kateřina Menšíková, et al.
International Journal of Hematology|May 4, 2010
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular responseEdgar Faber, David Friedecký, Katerina Micová, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Open Biology|January 8, 2016
Dr Jekyll and Mr Hyde: a strange case of 5-ethynyl-2'-deoxyuridine and 5-ethynyl-2'-deoxycytidineAnna Ligasová, Radek Liboska, David Friedecký, et al.
Analytical and Bioanalytical Chemistry|May 27, 2026
Derivatisation-free FIA-MS/MS assay for rapid simultaneous screening of atypical myopathy biomarkers and acylcarnitine profiles from dried blood spotsMartina Kadláčková, Dana Dobešová, Eliška Ivanovová, et al.
Talanta|April 18, 2015
Oxidized phosphatidylcholines suggest oxidative stress in patients with medium-chain acyl-CoA dehydrogenase deficiencyLukáš Najdekr, Alžběta Gardlo, Lucie Mádrová, et al.
International Journal of Molecular Sciences|August 7, 2021
SLIDE-Novel Approach to Apocrine Sweat Sampling for Lipid Profiling in Healthy IndividualsAleš Kvasnička, David Friedecký, Alena Tichá, et al.
Alzheimer'S Research & Therapy|September 23, 2017
Metabolic status of CSF distinguishes rats with tauopathy from controlsRadana Karlíková, Kateřina Mičová, Lukáš Najdekr, et al.
Annals of Hematology|January 11, 2012
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical settingEdgar Faber, David Friedecký, Kateřina Mičová, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive PatientsJana Úlehlová, Barbora Piskláková, Eliška Ivanovová, et al.
Progress in Neurobiology|February 6, 2026
ABCA7 deficiency exacerbates glutamate excitotoxicity in Alzheimer's disease mice - a new pharmacological target for Glu-related neurotoxicityAnna Maria Górska, Irene Santos-García, Aleš Kvasnička, et al.
European Journal of Medical Research|January 6, 2024
Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosisKateřina Klíčová, Jan Mareš, Kateřina Menšíková, et al.
International Journal of Hematology|May 4, 2010
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular responseEdgar Faber, David Friedecký, Katerina Micová, et al.
Pageof 8